A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma-Reference-Cited by-同舟云学术

A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

Published:2009-01 Issue:7 Volume:27 Page:756-763
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Bedikian Agop Y.,Papadopoulos Nicholas E.,Kim Kevin B.,Hwu Wen-Jen,Homsi Jade,Glass Michelle R.,Cain Suzanne,Rudewicz Patrick,Vernillet Laurent,Hwu Patrick

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/07357900802709159

Reference27 articles.

1. Cancer Statistics, 2007

2. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

3. Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents

4. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM;2024-08-10

2. Drugs that modulate resistance to antitumor agents;Medicinal Chemistry of Anticancer Drugs;2023

3. Poly(ADP-ribose) polymerase inhibition: past, present and future;Nature Reviews Drug Discovery;2020-09-03

4. C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage;Frontiers in Oncology;2019-06-11

5. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics;Anti-Cancer Agents in Medicinal Chemistry;2019-05-31